$57.99
0.09% yesterday
NYSE, Sep 27, 10:00 pm CET
ISIN
US03770N1019
Symbol
APGE
Sector
Industry

Apogee Therapeutics Stock price

$57.99
+10.46 22.01% 1M
-10.12 14.86% 6M
+30.05 107.55% YTD
+36.53 170.22% 1Y
+36.76 173.15% 3Y
+36.76 173.15% 5Y
+36.76 173.15% 10Y
NYSE, Closing price Fri, Sep 27 2024
-0.05 0.09%
ISIN
US03770N1019
Symbol
APGE
Sector
Industry

Key metrics

Market capitalization $3.39b
Enterprise Value $2.72b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 4.25
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-143.76m
Free Cash Flow (TTM) Free Cash Flow $-111.14m
Cash position $676.23m
EPS (TTM) EPS $-2.28
P/E forward negative
Short interest 21.29%
Show more

Is Apogee Therapeutics a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.

Apogee Therapeutics Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Apogee Therapeutics forecast:

7x Buy
100%

Analyst Opinions

7 Analysts have issued a Apogee Therapeutics forecast:

Buy
100%

Financial data from Apogee Therapeutics

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
- -
-
100%
- Direct Costs 0.07 0.07
-
-
-0.07 -0.07
-
-
- Selling and Administrative Expenses 36 36
-
-
- Research and Development Expense 108 108
-
-
-144 -144
-
-
- Depreciation and Amortization 0.07 0.07
-
-
EBIT (Operating Income) EBIT -144 -144
-
-
Net Profit -118 -118
-
-

In millions USD.

Don't miss a Thing! We will send you all news about Apogee Therapeutics directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Apogee Therapeutics Stock News

Neutral
GlobeNewsWire
16 days ago
SAN FRANCISCO and WALTHAM, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD) ...
Neutral
GlobeNewsWire
19 days ago
SAN FRANCISCO and WALTHAM, Mass., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease and othe...
Neutral
GlobeNewsWire
about one month ago
Interim safety and pharmacokinetic data from Phase 1 healthy volunteers trial anticipated in 2025 Initiation of the first clinical trial of APG777 and APG990 combination expected to commence in 2025 with the potential for greater efficacy in atopic dermatitis and across I&I diseases SAN FRANCISCO and WALTHAM, Mass., Aug. 19, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a ...
More Apogee Therapeutics News

Company Profile

Apogee Therapeutics, Inc. operates as a biotechnology company. It offers treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD) and related inflammatory and immunology (I&I) indications. The company was founded in February 2022 and is headquartered in Waltham, MA.

Head office United States
CEO Michael Henderson
Founded 2022
Website www.apogeetherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today